APA (7th ed.) Citation

R, E., L, M., E, M., Z, T., A, S., M, B., . . . E, M. (2023). Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nature communications, 14(1), 4221. https://doi.org/10.1038/s41467-023-40022-5

Chicago Style (17th ed.) Citation

R, El-Botty, et al. "Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy and Palbociclib Resistant Metastatic Breast Cancers." Nature Communications 14, no. 1 (2023): 4221. https://doi.org/10.1038/s41467-023-40022-5.

MLA (9th ed.) Citation

R, El-Botty, et al. "Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy and Palbociclib Resistant Metastatic Breast Cancers." Nature Communications, vol. 14, no. 1, 2023, p. 4221, https://doi.org/10.1038/s41467-023-40022-5.